| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Urine samples were obtained from the patients who needed prostate biopsy following a digital rectal exam (DRE) before either biopsy. After isolation of RNA from each sample, quantitative RT-PCR was performed to detect 14 prostate cancer biomarkers. The amount of PCR product was estimated by delta Ct method. The delta Ct value was normalized against urine PSA expression and was used as urine biomarker value. We found that the underexpression of FGF7 was useful for a prostate cancer detection particularly to exceed PCA3 in the gray zone (serum PSA<10ng/ml), but the significant difference was not found. In the prostate cancer cases that endocrine therapy was provided, the likelihood that WDR19 underexpression characteristics could become the relapse predictor was shown.
|
